Insights / Resource Center
Resources
Presentations
Scientific Posters
Success Stories
Events
PepTalk: The Protein Science and Production Week 2026
January 19–22, Primrose Bio presents and exhibits at PepTalk, San Diego, CA.
Antibody Engineering & Therapeutics US 2025
December 14–17, Primrose Bio presents and exhibits at AET US 2025.
PEGS Europe 2025: Accelerating Protein Therapeutics with Pfast™
November 11–13, Primrose Bio presents and exhibits at PEGS Europe 2025.
Presentations
Accelerating Antibody Screening with a Scalable Protein Expression Platform
Diane Retallack, PhD at the PepTalk: The Protein Science and Production Week, January 2026
Pfast™ Protein Expression: A Rapid, Robust Solution for Accelerating Antibody Screening
Diane Retallack, PhD at the Antibody Engineering & Therapeutics, December 2025
Achieving High Quality Efficient mRNA Synthesis for streamlined and cost-effective manufacturing
Helge Zieler, PhD and Khaled Yamout at a webinar with Nucleic Acid Insights
No Compromises: Engineered RNA polymerases for high quality, low-cost mRNA manufacturing
Helge Zieler, PhD at the 13th International mRNA Health Conference in Berlin, November 2025.
Engineered Enzymes Powering the Future of mRNA Therapeutics
Sabrina Baffert at the 13th International mRNA Health Conference in Berlin, November 2025.
Pfast™ Protein Expression: A Rapid, Robust Solution for Accelerating Biotherapeutic Screening
Russell Coleman at a webinar with Antibody Engineering & Therapeutics, May 2025
Scientific Posters
Presented at PepTalk The Protein Science and Production Week: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity
ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs As an example of the workflow, an...
Presented at Antibody Engineering & Therapeutics US 2025: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity
ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs. As an example of the workflow, an...
Presented at 13th International mRNA Health Conference: Prima RNApols™: Engineered Enzymes Powering the Future of mRNA Therapeutics
ABSTRACT: The field of mRNA therapeutics is rapidly developing across a wide range of applications, including infectious diseases, rare disorders, protein replacement, and cancer immunotherapy....
Case Studies
Pfenex
Recombinant Erwinia Asparaginase Production
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Lymphoblastic lymphoma (LBL) is a rare, fast-growing, aggressive subtype of non-Hodgkin’s lymphoma most often seen in teenagers and young adults.
Pfenex
Production of disulfide-rich cow knob domain antibodies: picobodies™
About 10% of cow antibodies have exceptionally long heavy chain CDR3 regions, including a stalk and knob region.
Pfenex
Multimeric vhh nanobody expression
Pfenex
Fab antibody fragment titer improvement
Anti-IL-4 Conjugate Vaccine Prepared with PeliCRM197 is More Immunogenic than KLH Analog
Comparable Immunogenicity Observed in Peptides Coupled to PeliCRM197 and KLH in a Murine Model
In this case study, 3 peptides (peptides #5, #6, and #7) directed to one therapeutic target were conjugated to either CRM197 (a non-toxic diphtheria toxin mutant) produced with Pfenex Expression Technology® or to KLH (keyhole limpet hemocyanin).
Success Stories
Manufacturing of RYLAZE utilizes Pfenex Expression Technology
Hear from the senior director for the biologics development team at Jazz Pharmaceuticals about the RYLAZE manufacturing process.